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ABSTRACT
Rationale Arikace is a liposomal amikacin preparation
for aerosol delivery with potent Pseudomonas
aeruginosa killing and prolonged lung deposition.
Objectives To examine the safety and efﬁcacy of
28 days of once-daily Arikace in cystic ﬁbrosis (CF)
patients chronically infected with P aeruginosa.
Methods 105 subjects were evaluated in double-blind,
placebo-controlled studies. Subjects were randomised to
once-daily Arikace (70, 140, 280 and 560 mg; n=7, 5,
21 and 36 subjects) or placebo (n=36) for 28 days.
Primary outcomes included safety and tolerability.
Secondary outcomes included lung function (forced
expiratory volume at one second (FEV1)), P aeruginosa
density in sputum, and the Cystic Fibrosis Quality of Life
Questionnaire—Revised (CFQ-R).
Results The adverse event proﬁle was similar among
Arikace and placebo subjects. The relative change in
FEV1 was higher in the 560 mg dose group at day 28
(p=0.033) and at day 56 (28 days post-treatment,
0.093L±0.203 vs −0.032L±0.119; p=0.003) versus
placebo. Sputum P aeruginosa density decreased >1 log
in the 560 mg group versus placebo (days 14, 28 and
35; p=0.021). The Respiratory Domain of the CFQ-R
increased by the Minimal Clinically Important Difference
(MCID) in 67% of Arikace subjects (560 mg) versus
36% of placebo (p=0.006), and correlated with FEV1
improvements at days 14, 28 and 42 (p<0.05). An
open-label extension (560 mg Arikace) for 28 days
followed by 56 days off over six cycles conﬁrmed durable
improvements in lung function and sputum P aeruginosa
density (n=49).
Conclusions Once-daily Arikace demonstrated acute
tolerability, safety, biologic activity and efﬁcacy in
patients with CF with P aeruginosa infection.
INTRODUCTION
Cystic ﬁbrosis (CF) is a life-shortening genetic
disease affecting over 70 000 CF patients world-
wide. CF is caused by mutations in the CF trans-
membrane conductance regulator (CFTR) gene.1 2
Morbidity and mortality associated with chronic
Pseudomonas aeruginosa lung infection affects
approximately 80% of CF patients by adulthood.3
4 Although chronic P aeruginosa infection acceler-
ates the loss of lung function and is an independent
contributor to mortality,5 more recent studies have
reported reduced effects of Pseudomonas infection
on long-term patient outcomes.6 7
Inhaled antibiotics, including aztreonam for inhal-
ation solution (AI), colistimethate sodium dry
powder (Colobreathe), and tobramycin inhalation
solution (TIS) are approved for use in CF patients
with chronic P aeruginosa infection.8–13 All three
reduce bacterial density in CF sputum, stabilise lung
function, and have become important components of
CF care. TIS and AI are Federal Drug Administration
(FDA) approved for use in the USA, while TIS, AI
and Colobreathe dry powder inhaler are approved in
Europe. Recent studies examining cycled use of AI
over 18mos in CF patients chronically infected with
P aeruginosa indicate that lung function improve-
ments gained during 28 days of treatment are typic-
ally 3–5% above baseline values after the ﬁrst three
treatment cycles, with decline towards baseline off-
treatment.11 14 Similar ﬁndings have been reported
with TIS, with <5% improvements in lung function
relative to baseline observed after the ﬁrst treatment
cycle.15 Two recent head-to-head open-label trials of
AI compared with TIS, and colistimethate sodium
dry powder compared with TIS have shown that
their effects on FEV1 are small, particularly following
three treatment cycles.13 16 This may reﬂect increased
use of anti-Pseudomonas antibiotics in the current era
of CF care, highlighting the need for novel
approaches to treat Pseudomonas infection.
Arikace is a unique formulation that encapsulates
aqueous amikacin in neutral liposomes composed of
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Key messages
What is the key question?
▸ To examine the safety and efﬁcacy of 28 days
of once-daily Arikace in cystic ﬁbrosis (CF)
patients chronically infected with Pseudomonas
aeruginosa.
What is the bottom line?
▸ Our data provide evidence for the short-term
safety, tolerability, biologic activity and efﬁcacy
of nebulised Arikace in CF patients chronically
infected with P aeruginosa.
Why read on?
▸ Our results with Arikace may contribute to
novel utilisation of topical antibiotics to treat
Pseudomonas infection in CF patients.
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dipalmitoyl-phosphatidylcholine (DPPC) and cholesterol, and is
delivered to patients using an optimised investigational eFlow
Nebuliser System.17 Upon nebulisation, Arikace liposomes
(∼300 nm) penetrate CF sputum, are lysed by local
P aeruginosa-derived products, and have a prolonged lung half-
life (several hours) relative to liposome-free antibiotics.18 19
Arikace reduces P aeruginosa density in animal models of lung
infection, and studies in preclinical model systems and in human
subjects support once-daily dosing.20 21
In this report, we describe the safety, tolerability, efﬁcacy and
pharmacokinetics of four doses of once-daily Arikace for
28 days compared with placebo in CF patients chronically
infected with P aeruginosa.
METHODS
The Phase II Arikace programme included randomised, double-
blind, placebo-controlled, multiple-dose, multicentre trials in sub-
jects with CF. Parallel studies were conducted in Europe (13 sites)
and the USA (19 sites). Institutional Review Board, IEC approvals
and informed consents were obtained at each site, and for all study
subjects. The studies were performed in accordance with
International Conference on Harmonisation, Good Clinical
Practice guidelines, and the Declaration of Helsinki. Pooled ana-
lyses of common endpoints between the placebo-controlled
European and US studies were established a priori (safety, adverse
events (AE), serious AE (SAE), lung function, CFQ-R, microbiol-
ogy and pharmacokinetics).
Subjects
Inclusion criteria included a CF diagnosis (sweat Cl–
>60 mmol/L or two CF-associated mutations with organ system
manifestation of CF), age ≥6 yrs, FEV1 ≥40% predicted,
chronic P aeruginosa infection (four positive cultures over
2 years, including one within 3 months before screening and
one at screening), clinical stability off of inhaled, or intravenous
antibiotics 28 days before dosing, and no known allergy to ami-
kacin. Additional information regarding study subjects is found
in the online supplement.
Study design
The preclinical programme for Arikace development provided
safety and efﬁcacy coverage for dosing up to 560 mg once daily
(multiple 28-day cycles). In Europe, subjects were randomised
to once-daily Arikace (280 mg or 560 mg) or placebo for
28 days, followed by 28 days off study drug. Cohort 1 subjects
were randomised to 280 mg or placebo, and cohort 2 subjects
to 560 mg or placebo, each in a 2 : 1 ratio (equal randomisation
for Arikace study arms and combined placebo). Based on initial
FDA recommendations for a dose-ascending study design,
patients in the USA were equally randomised to once-daily
Arikace (70 mg or 140 mg) or placebo. After enrolling 19 sub-
jects, a prespeciﬁed Data Safety Monitoring Board (DSMB)
safety review (coupled with examination of preliminary safety
and efﬁcacy data from the European trial) recommended
amending the US protocol to dosing with 560 mg Arikace
versus placebo (1 : 1 randomisation). Following subsequent FDA
approval, the US study examined 560 mg Arikace nebulised
once daily versus placebo, with postdosing monitoring for
56 days (weekly visits for 28 days of treatment, then visits at
days 42 and 56 off study drug). To provide complete data on
safety and tolerability, data from all dose groups in both trials
are included. Open-label extension details are in the online
supplement.
Endpoints
The primary study objective was safety and tolerability (includ-
ing vital signs, predose and postdose lung function (acute toler-
ability), pulse oximetry, AEs, haematology, clinical chemistry,
urinalysis, physical examinations, audiology and ECG and chest
x-rays as needed). Secondary objectives are described in the
online supplement.
Pharmacokinetic Analysis is included in the online
supplement.
Statistical analyses of safety data
Baseline characteristics are described using summary statistics.
Incidence of AEs by MedDRA system organ class and preferred
term are displayed by treatment group. If an AE was reported
more than once during the study period for a given patient, the
greatest severity and the worst-case attribution are presented in
the summary tables. Fisher’s exact tests were used to compare
AE rates between the dose cohorts and placebo cohort.
Differences in treatment arms for predose measurements of
pulmonary function over time were compared using repeated
measures ANOVA (rANOVA), adjusting for bronchodilator use.
Treatment differences with respect to the changes from baseline
to each measured study day in log10CFU/g, were similarly com-
puted using ANOVA with no adjustments made for multiple
comparisons. A non-parametric correlation of change in
log10CFU/g with baseline minimal inhibitory concentration
(MIC) was computed for each treatment group and displayed
graphically by National Committee for Clinical Laboratory
Standards-Susceptible, Intermediate, Resistant (NCCLS-SIR) cat-
egories of baseline MIC. Treatment differences in absolute and
relative change in CFQ-R domain scores were computed using
analysis of covariance (ANCOVA), adjusting for baseline scores;
the proportion of patients with minimum clinically important
difference on the respiratory scale by treatment group were
compared by treatment group using a χ2 statistic. Statistical ana-
lyses were performed using SAS V.9.1 and S-PLUS 2000.
The study was adequately powered for the primary objective
(safety) and secondary objectives. A minimum of 20 subjects
were required in any cohort to have an 80% chance of detecting
any AE if the underlying rate was 8% or higher. Analyses were
performed on all subjects who received at least one dose of
study drug (safety population).
Additional statistical analyses, including efﬁcacy outcome
measures, are included in the online supplement.
RESULTS
Subjects
A total of 105 CF subjects meeting enrolment criteria were
screened, randomised and dosed in one of four Arikace dose
groups or placebo (ﬁgure 1, and enrolment segregated by US
and European sites: see online supplementary ﬁgure S1).
Subjects (across both studies) were randomised to receive 70 mg
(n=7), 140 mg (n=5), 280 mg (n=21), 560 mg (n=36), or
placebo (n=36). Baseline demographic characteristics (all sub-
jects) are provided in table 1 (and for each study: see online
supplementary tables S1 and S2). Age, gender, body mass index
(BMI), lung function (FEV1% predicted) and chronic TIS use
were generally similar, but with milder disease in the 140 mg
dose group (higher FEV1 and BMI, US study, n=5), and
younger age in the 280 mg cohort (16 years, European study,
n=21). Mucoid P aeruginosa infection rates were similar in the
European and US studies (85% and 89%, respectively), while
chronic TIS use was lower in the European versus US subjects
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(deﬁned as >three 28-day cycles in the preceding 12 months,
19% and 35%, respectively). The European cohort was younger
(median age of 16.5 years (±6 years, SD) compared with
30.5 years (±8 years, SD) for the US cohort), but with similar
lung function (median FEV1% predicted, 65.7% (±20%) for
Europe versus 65.3% (±19%) for USA).
Safety and adverse event proﬁle
Adherence and drug accountability was monitored by calculat-
ing the used and unused treatment vials returned at study visits.
While an imperfect method to assess adherence, no difference
was observed between the placebo and treatment groups
(>90%). The overall frequency of AEs was similar across the
Arikace dose groups and placebo, with no statistically signiﬁcant
differences. Acute tolerability was similar, with 2.8% of
Arikace-treated subjects and 11.1% of placebos demonstrating a
drop in FEV1 of ≥15% within 30 min of dosing. table 2 sum-
marises AEs that occurred in ≥8% of Arikace-treated patients.
The total number of subjects reporting at least one AE in the
560 mg Arikace group was 20 (55.6%) compared with 22
(61.1%) in the placebo group. The most frequent AEs were
respiratory, occurring in 45% of all Arikace-treated versus 39%
of placebo-treated subjects. The AE proﬁle was generally similar,
with more dysphonia reported in the high-dose Arikace group
(8% vs 0%). Five subjects in the Arikace groups discontinued
study drug (70 and 560 mg dose groups; due to respiratory
events, dysphonia, laryngitis and tinnitus) compared with one
placebo (respiratory event). AEs considered severe (grade 3) are
listed in online supplementary table S3, and all related AEs are
listed in online supplementary table S4 (all reported AEs are
listed in online supplementary table S5). Additionally, eight
SAEs occurred in the Arikace treatment groups (respiratory),
including ﬁve pulmonary exacerbations with hospitalisation
(four after Arikace dosing). Two placebo subjects were hospita-
lised (one for a pulmonary exacerbation, day 43; second subject
was hospitalised twice (migraine, day 46 and elevated LFTs, day
79)). There were no other clinically signiﬁcant changes in
laboratory ﬁndings. Results from audiology testing (see online
supplementary table S6) showed no differences between groups.
Spirometry
Pulmonary function data are summarised in ﬁgure 2. Due to the
short duration of the placebo-controlled trial (28 days of
dosing), data in the ﬁgure are presented as mean raw litre ﬂows
and SD (reduced risk of height measurement errors that can
occur when reporting the FEV1% predicted). FEV1 in the
placebo, 70 and 140 mg dose groups demonstrated no consist-
ent trends over the 28-day treatment period. By contrast, the
280 mg and 560 mg dose groups demonstrated rapid, sustained
and signiﬁcant increases in FEV1 at days 14 and 28 compared
with pretreatment values and placebo. In the 280 mg dose
group, the change in FEV1 from baseline was higher at day 28
compared with placebo (0.101L±0.128 vs 0.011L±0.101;
p=0.009), returning to pretreatment values by day 56 (28 days
off study drug). In the 560 mg dose group, the change in FEV1
from baseline was higher at day 28 compared with placebo
Figure 1 Patient enrolment across
the two Arikace studies. In the
European study, 75 patients were
screened, and 66 were randomised. In
the US study, 56 patients were
screened, and 46 were randomised.
*Across all randomised subjects, seven
subjects withdrew consent prior to
dosing. Data shown is for the 105
subjects dosed at least once with
Arikace or placebo.
Table 1 Demographic summary of all cystic fibrosis patients dosed in the European and US trials (mean (SD))
Arikace 70 mg (n=7) Arikace 140 mg (n=5) Arikace 280 mg (n=21) Arikace 560 mg (n=36) Placebo (n=36)
Age, years 33.1 (9.7) 35.4 (6.0) 16.0 (5.3) 23.0 (12.6) 20.3 (7.7)
Females, n (%) 6 (85.7) 1 (20.0) 16 (76.2) 15 (41.7) 20 (55.6)
FEV1 (L) 1.87 (0.41) 2.88 (0.40) 2.022 (0.79) 2.19 (0.87) 2.13 (0.70)
FEV1 (% predicted) 59.29 (12.60) 70.40 (10.09) 66.40 (20.00) 66.39 (17.44) 67.86 (19.36)
FEF25–75% (L/s) 0.96 (0.52) 1.91 (0.92) 1.60 (0.90) 1.692 (0.933) 1.53 (0.87)
FVC (L) 3.00 (0.60) 4.25 (0.42) 2.80 (1.10) 3.01 (1.20) 3.08 (1.09)
BMI (kg/m2) 22.97 (1.57) 26.33 (3.19) 18.06 (2.29) 20.38 (4.06) 19.90 (3.46)
BMI, body mass index; FVC, forced vital capacity; FEF, forced expiratory flow.
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(0.081L±0.161 vs 0.011L± 0.101; p=0.033), persisting
through day 56 (0.093L±0.203 vs −0.032L±0.119; p=0.003).
This corresponded to an % FEV1 predicted treatment effect at
day 56 of 12.5%.
Microbiology
The mean baseline log10 P aeruginosa sputum density was 7.031
(±1.496) in the placebo group and 8.392 (±0.510), 8.000
(±1.047), 6.925 (±1.265), and 7.444 (±1.038) in the 70, 140,
Table 2 Adverse events (AE) occurring in ≥8% in Arikace-treated patients compared with placebo (European and US trials combined)
Arikace 70 mg (n=7)
(%)
Arikace 140 mg (n=5)
(%)
Arikace 280 mg (n=21)
(%)
Arikace 560 mg (n=36)
(%)
Placebo (n=36)
(%)
Patients with at least one AE 7 (100) 4 (80) 13 (61.9) 20 (55.6) 22 (61.1)
Nausea 2 (29) 0 (0) 0 (0) 3 (8) 1 (3)
Chills 0 (0) 1 (20) 0 (0) 2 (6) 1 (3)
Fatigue 2 (29) 1 (20) 0 (0) 2 (6) 1 (3)
Vessel puncture site haematoma 1 (14) 0 (0) 0 (0) 0 (0) 1 (3)
Pyrexia 0 (0) 1 (20) 1 (5) 3 (8) 3 (8)
Sinusitis 0 (0) 0 (0) 2 (10) 2 (6) 3 (8)
Creatinine renal clearance 0 (0) 1 (20) 0 (0) 0 (0) 1 (3)
Hyperglycaemia 0 (0) 1 (20) 0 (0) 0 (0) 1 (3)
Arthralgia 0 (0) 0 (0) 0 (0) 3 (8) 1 (3)
Headache 0 (0) 0 (0) 2 (10) 2 (6) 3 (8)
Cough 1 (14) 0 (0) 2 (10) 6 (17) 4 (11)
Dyspnoea 0 (0) 1 (20) 0 (0) 1 (3) 2 (6)
Dysphonia 0 (0) 0 (0) 0 (0) 3 (8) 0 (0)
Haemoptysis 2 (29) 1 (20) 2 (10) 1 (3) 3 (8)
Lung disorder (pulmonary
exacerbations)
2 (29) 1 (20) 1 (5) 9 (25) 6 (17)
Pharyngo-laryngeal pain 1 (14) 0 (0) 0 (0) 3 (8) 1 (3)
Productive cough 2 (29) 1(20) 3 (14) 3 (8) 5 (14)
Pulmonary congestion 1 (14) 0 (0) 0 (0) 1 (3) 1 (3)
Rales 0 (0) 1 (20) 0 (0) 3 (8) 0 (0)
Rhinitis allergic 0 (0) 0 (0) 2 (10) 0 (0) 0 (0)
Rhinorrhoea 0 (0) 0 (0) 0 (0) 3 (8) 3 (8)
Rhonchi 0 (0) 0 (0) 0 (0) 3 (8) 0 (0)
Sinus disorder/congestion 0 (0) 1 (20) 0 (0) 1 (3) 4 (11)
Throat tightness 0 (0) 0 (0) 0 (0) 3 (8) 0 (0)
Wheezing 2 (29) 0 (0) 0 (0) 3 (8) 1 (3)
Figure 2 Change in FEV1 (L) from
baseline through day 56. Filled
squares, solid line=Arikace 560 mg,
*p=0.033 at day 28, *p=0.003 at day
56 (compared with placebo). Filled
triangles, solid line=Arikace 280 mg,
*p=0.009 at day 28 (compared with
placebo). Open squares, dashed
line=Arikace 140 mg. Open diamonds,
dashed line=Arikace 70 mg. Open
circles, dashed line=placebo. The
values above the abscissa are the
number of subjects in each dose
cohort providing data at each time
point (70 mg/140 mg/280 mg/560 mg/
placebo).
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280 and 560 mg dose groups, respectively. Rapid and sustained
reduction of Paeruginosa sputum densities was noted for the 560
mg dose group compared with placebo (p=0.007) (ﬁgure 3).
P aeruginosa sputum density remained reduced relative to base-
line and placebo for the 560 mg dose group at day 35 (7 days off
of study drug, p=0.021). Amikacin MIC for 50% of organisms
(MIC50) and MIC for 90% of organisms (MIC90) values did not
change over the 28-day treatment periods relative to placebo
(data not shown).
Patient-reported outcomes is included in the online supple-
mentary ﬁgure S2.
Pharmacokinetic/pharmacodynamic results is included in the
online supplement.
Open-label extension
A subgroup of subjects in the European trial (n=49) were
enrolled into an open-label extension study to evaluate the
safety, tolerability and efﬁcacy of six repeat cycles of Arikace
treatment (560 mg daily for 28 days) followed by 56 days off
treatment. Baseline characteristics of this group are included in
table 3, and changes in FEV1% predicted, P aeruginosa sputum
CFUs/g, and the distribution of median MIC50 of Pseudomonas
isolates are shown in ﬁgures 4, 5, and online supplementary
ﬁgure S3, respectively. Repeat dosing with Arikace was well tol-
erated with four subjects discontinuing study drug over six
cycles and 15 subjects experiencing SAEs (pulmonary exacerba-
tions requiring treatment with antibiotics). Online supplemen-
tary table S7 summarises the AEs reported during the
open-label extension. Of 49 subjects, 48 experienced at least
one AE, with approximately one-third experiencing an SAE
(none related to study drug). The majority of reported AEs
(59%) were mild and most were classiﬁed as either infectious or
respiratory. Of the 351 total AEs reported, 33 were categorised
as possibly or probably related to study drug, and there were no
deaths. FEV1% predicted (ﬁgure 4) demonstrated rapid and sus-
tained increases for each treatment cycle, with an estimated
mean increase of FEV1 (%) of 7.9% from baseline to end of the
28-day dosing period for the six cycles (p<0.0001), and a mean
increase of 5.7% from baseline to end of day 84 (56 days post-
treatment) across all six cycles (p=0.0001). P aeruginosa CFU/g
were reduced across the treatment cycles (log10 CFUs of −0.53
at day 28 of the ﬁrst treatment cycle (p=0.025)), with an esti-
mated mean change in log10 CFUs of −0.60 from baseline over
all measurements (p=0.003) across all six treatment cycles
(ﬁgure 5). Median MIC50 values for P aeruginosa isolates
demonstrated no signiﬁcant change over all cycles (see online
supplementary ﬁgure S3).
DISCUSSION
Chronic P aeruginosa infection is a common problem in CF
associated with accelerated loss of lung function, and is a pre-
dictor of morbidity and mortality. In the Phase II studies
described, once-daily liposomal amikacin improved lung func-
tion, reduced the P aeruginosa sputum density, and improved
patient-reported respiratory symptoms in CF patients over
28 days of treatment. Improvements in lung function persisted
Table 3 Demographic information of cystic fibrosis subjects
enrolled in the open-label extension study evaluating repeated
cycles of once daily 560 mg Arikace (mean (SD)—all from European
sites)
Arikace 560 mg
(n=33)
Placebo
(n=16) Total (n=49)
Age (yr) 17.7 (6.1) 16.7 (6.7) 17.4 (6.2)
Females, n (%) 21 (63.6) 8 (50.0) 29 (59.2)
FEV1 (L) 1.89 (0.77) 1.84 (0.80) 1.87 (0.772)
FEV1 (%
predicted)
59.5 (19.7) 58.5 (19.00) 59.2 (19.3)
FEF25–75% (L/sec) 1.33 (0.72) 1.35 (0.88) 1.34 (0.766)
FVC (L) 2.71 (1.12) 2.66 (1.12) 2.69 (1.109)
BMI (kg/m2) 18.65 (3.25) 17.95 (2.85) 18.43 (3.11)
Subjects are segregated by their original treatment assignment during the
randomised, double-blind placebo controlled trial that preceded the open-label trial.
BMI, body mass index; FVC, forced vital capacity; FEF, forced expiratory flow.
Figure 3 Change in sputum density
of Pseudomonas aeruginosa (log10
CFU/g) from baseline through day 35.
Filled squares, solid line=Arikace
560 mg, *p=0.007 at day 28,
*p=0.021 at day 35. Filled triangles,
solid line=Arikace 280 mg. Open
squares, dashed line=Arikace 140 mg.
Open diamonds, dashed line=Arikace
70 mg. Open circles, dashed
line=placebo. The values above the
abscissa are the number of subjects in
each dose cohort providing data at
each time point (70 mg/140 mg/
280 mg/560 mg/placebo).
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signiﬁcantly above that of placebo-treated patients for 28 days
post-treatment, and 56 days post-treatment over multiple cycles
relative to baseline values. These prolonged beneﬁts are novel
and provide support for further evaluation of Arikace. Our ﬁnd-
ings contrast with those recently reported with other cycled,
topical antibiotic preparations approved for the treatment of CF
patients infected with P aeruginosa, where lung function
returned towards pretreatment values off-cycle.9 11 14 15 Recent
results of an open-label trial of nebulised cayston and TIS in CF
patients with moderate lung disease reported that FEV1 changed
minimally over three 28 days treatment cycles (+2.05% and
−0.66% respectively, relative to baseline).16 Additionally, a
recent phase III open-label study of colistimethate sodium dry
powder in CF patients reported non-inferiority relative to TIS
over three 28 day treatment cycles, with minimal change in lung
function.13 Baseline lung function in these open-label studies
was similar to ours (FEV1=49–59%), suggesting that this was
not responsible for the differences observed across the trials.
Safety and tolerability of Arikace were supported by the AE
and SAE proﬁle, with similar rates of drug discontinuation
across the Arikace and placebo subjects. There were no differ-
ences in audiologic or renal safety outcomes for the Arikace
groups relative to placebo, which are relevant for the develop-
ment of chronic nebulised aminoglycosides. The amikacin
MIC50 of P aeruginosa isolates from the Arikace subjects (rando-
mised and open-label extension) did not show appreciable
increases over single or numerous treatment cycles. Although
longer and larger trials of Arikace will be necessary to conﬁrm
our ﬁndings, the results provide reassurance for the design and
execution of deﬁnitive trials.
Liposomal components of Arikace are found in lung surfac-
tant, which is normally cleared rapidly by several lung cell
types, (type II pneumocytes, Clara cells, and macrophages).22
Turnover rates in the adult human lung for DPPC and choles-
terol are approximately 79 mg/h and 24 mg/day, respectively.23–
25 Following a single 560 mg Arikace dose (via eFlow with 30%
drug deposition), approximately 73 mg of DPPC (29 mg to lung
periphery) and 36 mg of cholesterol (14 mg to lung periphery)
are delivered to the lung. Repeated dosing over prolonged
periods in animal models has little lasting effect on lung hist-
ology or pulmonary macrophage function.20 26 Together, these
novel characteristics make Arikace unique among nebulised
antibiotics.
The pharmacokinetics and pharmacodynamics of Arikace
demonstrated high sputum-amikacin levels, low systemic levels,
and dose-dependent relationships between Arikace and both
FEV1 and FEF25−75% improvements. These pharmacokinetic
data (see online supplementary table S8) support prolonged
deposition of amikacin in the lung, with stable airway clearance,
but increasing systemic clearance of amikacin with increasing
Arikace exposure. This is likely a product of enhanced lung
deposition, and the safety of this systemic exposure will need to
be considered in future study designs. The data from the open-
label extension (ﬁgure 4 and see online supplementary table S7)
support long-term tolerance over repeated cycles, but this will
also require conﬁrmation in future studies. The consistent
reductions in P aeruginosa density (ﬁgure 5), coupled with pro-
longed improvements in lung function and respiratory symp-
toms over repeated cycles (ﬁgure 4), support a prolonged
antimicrobial effect. The MIC50 for P aeruginosa isolates was
Figure 4 Change in FEV1 (%
predicted) from baseline through cycle
6 of Arikace. Each cycle consisted of
28 days of once daily Arikace (560 mg)
followed by 56 days off study drug.
Each shaded box is a treatment cycle.
Study days (every 2 weeks) are as
shown on the abscissa, with the
number of subjects at each time point
as noted immediately above the study
days. *p<0.0001 for FEV1 at end of
treatment following six cycles
compared with baseline; **p=0.0001
for FEV1 at 56 days post-treatment
following six cycles compared with
baseline.
Figure 5 Change in sputum density
of Pseudomonas aeruginosa (log10
CFU/g) from baseline through cycle 6
of Arikace. Each set of three bars is
the change in sputum P aeruginosa
density compared with baseline (day 1
of cycle 1) for days 1 (white), 14
(gray), and 28 (black) of each
respective Arikace cycle. *p=0.003 for
change in CFU across all of the Arikace
treatment cycles relative to baseline
(cycle 1, day 1).
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increased in later cycles, but did not demonstrate a clear trend
over the entire open-label study, or within individual cycles (see
online supplementary ﬁgure S3). Monitoring of aminoglycoside
susceptibility patterns will be needed in future studies of
Arikace, including resistance to amikacin and tobramycin.
Important limitations in the study include the small lower dose
Arikace cohorts, the younger age and relatively more severe lung
disease in the European cohorts, and the relatively low treatment
with chronic inhaled tobramycin (likely reﬂective of strict deﬁn-
ition criteria). Despite these limitations, our data provide evi-
dence for the short-term safety, tolerability and efﬁcacy of
nebulised Arikace in CF patients chronically infected with Paeru-
ginosa. The current data supports future studies with a once-daily
560 mg dose using a rapid delivery nebuliser, with prolonged off-
treatment cycles. Higher doses, or more frequent dosing, may be
appropriate for other conditions (eg, non-tuberculous mycobac-
teria infection), and are under investigation (NCT01315236).
These dosing features may potentially enhance adherence and
minimise chronic drug exposure, thereby reducing the risk of
long-term side effects. These beneﬁts may signal a new approach
for the management of chronic pulmonary infections utilising
antibiotics combined with neutral liposomes.
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